The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype
Open accessAbstract
BACKGROUND AND OBJECTIVES: Hemolytic uremic syndrome (HUS) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. Most childhood cases are caused by Shiga toxin-producing bacteria. The other form, atypical HUS (aHUS), accounts for 10% of cases and has a poor prognosis. Genetic complement abnormalities have been found in aHUS. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: We screened 273 consecutive patients with aHUS for complement abnormalities and studied their role in predicting clinical phenotype and response to treatment. We compared mutation frequencies and localization and clinical outcome in familial (82) and sporadic (191) cases. RESULTS: In >70% of sporadic and familial cases, gene mutations, disease-associated factor H (CFH) polymorphisms, or anti-CFH autoantibodies were found. Either mutations or CFH polymorphisms were also found in the majority of patients with secondary aHUS, suggesting a genetic predisposition. Familial cases showed a higher prevalence of mutations in SCR20 of CFH and more severe disease than sporadic cases. Patients with CFH or THBD (thrombomodulin) mutations had the earliest onset and highest mortality. Membrane-cofactor protein (MCP) mutations were associated with the best prognosis. Plasma therapy induced remission in 55 to 80% of episodes in patients with CFH, C3, or THBD mutations or autoantibodies, whereas patients with CFI (factor I) mutations were poor responders. aHUS recurred frequently after kidney transplantation except for patients with MCP mutations. CONCLUSIONS: Results underline the need of genetic screening for all susceptibility factors as part of clinical management of aHUS and for identification of patients who could safely benefit from kidney transplant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Self-citationCaprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732
Self-citationThrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome
Delvaeye, M., Noris, M., De Vriese, A., Esmon, C. T., Esmon, N. L., Ferrell, G., Del-Favero, J., Plaisance, S., Claes, B., Lambrechts, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810739 · Cited by 554
Self-citationAnti–Factor H Autoantibodies Associated with Atypical Hemolytic Uremic Syndrome
Dragon-Durey, M.-A. G. A., Loirat, C., Cloarec, S., Macher, M.-A., Blouin, J., Nivet, H., Weiss, L., Fridman, W. H., & Frémeaux-Bacchi, V. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004050380 · Cited by 502
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura
Ruggenenti, P., Noris, M., & Remuzzi, G. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.060003831.x · Cited by 489
Self-citationMutations in Complement Factor I Predispose to Development of Atypical Hemolytic Uremic Syndrome
Kavanagh, D., Kemp, E. J., Mayland, E., Winney, R. J., Duffield, J. S., Warwick, G., Richards, A., Ward, R., Goodship, J. A., & Goodship, T. H. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010103 · Cited by 475
Self-citationde Jorge, E. G., Harris, C. L., Esparza-Gordillo, J., Carreras, L., Arranz, E. A., Garrido, C. A., López-Trascasa, M., Sánchez-Corral, P., Morgan, B. P., & de Córdoba, S. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603420103 · Cited by 447
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome
Frémeaux-Bacchi, V., Miller, E. C., Liszewski, M. K., Strain, L., Blouin, J., Brown, A. L., Moghal, N., Kaplan, B. S., Weiss, R. A., Lhotta, K., et al. (2008) · Blood · doi:10.1182/blood-2008-01-133702 · Cited by 372
Self-citationMoore, I., Strain, L., Pappworth, I., Kavanagh, D., Barlow, P. N., Herbert, A. P., Schmidt, C. Q., Staniforth, S. J., Holmes, L. V., Ward, R., et al. (2010) · Blood · doi:10.1182/blood-2009-05-221549 · Cited by 357
Self-citationFactor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency
Józsi, M., Licht, C., Strobel, S., Zipfel, S. L. H., Richter, H., Heinen, S., Zipfel, P. F., & Skerka, C. (2008) · Blood · doi:10.1182/blood-2007-09-109876 · Cited by 354
Self-citation
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Self-citationAtypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Self-citationSyndromes of Thrombotic Microangiopathy
George, J. N., & Nester, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1312353 · Cited by 1,279
Complement System Part II: Role in Immunity
Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00257 · Cited by 1,051
Schwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly‐Smith, L., Delaney, M., Dunbar, N. M., Witt, V., Wu, Y., & Shaz, B. H. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21470 · Cited by 793
Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaimé, F., Dragon-Durey, M.-A., Ngo, S., Moulin, B., Servais, A., Provot, F., Rostaing, L., et al. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04760512 · Cited by 714
Goodship, T. H. J., Cook, H. T., Fakhouri, F., Fervenza, F. C., Frémeaux-Bacchi, V., Kavanagh, D., Nester, C. M., Noris, M., Pickering, M. C., Rodríguez de Córdoba, S., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.005 · Cited by 701
Self-citationConnelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Atypical hemolytic uremic syndrome
Loirat, C., & Frémeaux-Bacchi, V. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-60 · Cited by 669
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
International, F. H., Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., et al. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3076-8 · Cited by 596
Fakhouri, F., Zuber, J., Frémeaux-Bacchi, V., & Loirat, C. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30062-4 · Cited by 571
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense
Ricklin, D., Reis, E. S., Mastellos, D. C., Gros, P., & Lambris, J. D. (2016) · Immunological Reviews · doi:10.1111/imr.12500 · Cited by 484
Licht, C., Greenbaum, L. A., Muus, P., Babu, S., Bedrosian, C. L., Cohen, D. J., Delmas, Y., Douglas, K., Furman, R. R., Gaber, O. A., et al. (2015) · Kidney International · doi:10.1038/ki.2014.423 · Cited by 420
Self-citationSTEC-HUS, atypical HUS and TTP are all diseases of complement activation
Noris, M., Mescia, F., & Remuzzi, G. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.195 · Cited by 383
Self-citationThrombotic Microangiopathy and the Kidney
Brocklebank, V., Wood, K. M., & Kavanagh, D. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00620117 · Cited by 373
Bresin, E., Rurali, E., Caprioli, J., Sanchez-Corral, P., Fremeaux-Bacchi, V., Rodriguez de Cordoba, S., Pinto, S., Goodship, T. H. J., Alberti, M., Ribes, D., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012090884 · Cited by 352
Self-citationAtypical Hemolytic Uremic Syndrome
Kavanagh, D., Goodship, T. H., & Richards, A. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.003 · Cited by 348
Self-citationExploring the genetic basis of early-onset chronic kidney disease
Vivante, A., & Hildebrandt, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.205 · Cited by 344
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy
Noris, M., Galbusera, M., Gastoldi, S., Macor, P., Banterla, F., Bresin, E., Tripodo, C., Bettoni, S., Donadelli, R., Valoti, E., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558296 · Cited by 341
Self-citationFakhouri, F., Hourmant, M., Campistol, J. M., Cataland, S. R., Espinosa, M., Gaber, A. O., Menne, J., Minetti, E. E., Provôt, F., Rondeau, E., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.034 · Cited by 305
Atypical aHUS: State of the art
Nester, C. M., Barbour, T., de Cordoba, S. R., Dragon-Durey, M. A., Fremeaux-Bacchi, V., Goodship, T. H. J., Kavanagh, D., Noris, M., Pickering, M., Sanchez-Corral, P., et al. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.03.246 · Cited by 299
Self-citationGreenbaum, L. A., Fila, M., Ardissino, G., Al-Akash, S. I., Evans, J., Henning, P., Lieberman, K. V., Maringhini, S., Pape, L., Rees, L., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.11.026 · Cited by 296
Jokiranta, T. S. (2017) · Blood · doi:10.1182/blood-2016-11-709865 · Cited by 280
Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review
Joseph, A., Cointe, A., Mariani Kurkdjian, P., Rafat, C., & Hertig, A. (2020) · Toxins · doi:10.3390/toxins12020067 · Cited by 278
How I treat thrombocytopenia in pregnancy
Gernsheimer, T., James, A. H., & Stasi, R. (2013) · Blood · doi:10.1182/blood-2012-08-448944 · Cited by 275
Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyó, J. M., Macía, M., Mendizábal, S., Praga, M., et al. (2015) · Nefrología · doi:10.1016/j.nefro.2015.07.005 · Cited by 272
Le Quintrec, M., Zuber, J., Moulin, B., Kamar, N., Jablonski, M., Lionet, A., Chatelet, V., Mousson, C., Mourad, G., Bridoux, F., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12077 · Cited by 268
Diseases of complement dysregulation-an overview
Wong, E. K. S., & Kavanagh, D. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0663-8 · Cited by 115
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003573 · Cited by 110
Gavriilaki, E., Anagnostopoulos, A., & Mastellos, D. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00337 · Cited by 106
Metadata
- Authors
- Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., Piras, R., Donadelli, R., Maranta, R., van der Meer, I., Conway, E. M., Zipfel, P. F., Goodship, T. H., & Remuzzi, G.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2010-10
- Volume
- 5
- Issue
- 10
- Pages
- 1844-1859
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2123753762
- Cited by
- 1,042
- References
- 32
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.